Recommended Combined Oral Contraceptive Brand
For a healthy woman of reproductive age without contraindications, start with a monophasic combined oral contraceptive containing 30-35 μg ethinyl estradiol plus norgestimate or levonorgestrel, choosing the formulation with the lowest copay on her insurance formulary. 1
Practical First-Line Recommendations
Many adolescent medicine providers and experts recommend beginning with a monophasic pill containing 30-35 μg ethinyl estradiol combined with norgestimate or levonorgestrel 1. Among low-dose pills, there are no clear data suggesting one formulation is superior to another for general contraceptive use, so cost and insurance coverage should guide the initial choice 1.
Specific brand example: Ortho Tri-Cyclen (ethinyl estradiol 35 μg + norgestimate in varying doses) is FDA-approved for contraception 2 and has been extensively studied, demonstrating:
- Contraceptive efficacy equivalent to other oral contraceptives 3, 4
- Favorable metabolic profile with increases in HDL cholesterol and decreases in LDL/HDL ratio 3, 5, 4
- Minimal androgenic effects 5, 4
- Good cycle control comparable to monophasic formulations 3
Key Eligibility Considerations
Before prescribing any combined hormonal contraceptive, blood pressure measurement is the only required clinical examination 6. The U.S. Medical Eligibility Criteria provides a categorical framework 7:
Category 1 (no restrictions): Healthy women under age 40, non-smokers, without cardiovascular risk factors 7
Category 2 (advantages generally outweigh risks): Women ≥40 years old without other risk factors 7
Category 3-4 (generally not recommended or contraindicated):
- Smokers ≥35 years, especially >15 cigarettes/day 8
- Uncontrolled hypertension (≥160/100 mmHg) 8
- History of venous thromboembolism or arterial disease 8
- Diabetes with vascular complications 8
Alternative Formulations to Consider
Monophasic vs. Triphasic: While triphasic formulations like Ortho Tri-Cyclen exist, many experts prefer starting with monophasic preparations for simplicity, then adjusting based on patient response 1. Monophasic pills deliver the same hormone dose daily during the active pill phase, making them easier to manage if pills are missed.
Lower-dose options: Ortho Tri-Cyclen Lo (25 μg ethinyl estradiol + norgestimate) demonstrated comparable efficacy with significantly better breakthrough bleeding rates compared to 20 μg formulations 9.
Newer estrogen alternatives: Estetrol-based COCs represent emerging options with potentially favorable hemostatic profiles 10, 11, though long-term safety data remain limited and these should not be considered first-line until more evidence accumulates.
Initiation Protocol
Timing: Combined hormonal contraceptives can be started at any time if reasonably certain the woman is not pregnant 12, 6
Back-up contraception needed if:
- Started >5 days after menstrual bleeding began: use barrier methods or abstain for 7 days 12, 6
- Started ≤5 days after menses: no additional protection needed 12, 6
Common Pitfalls to Avoid
Don't prescribe combined hormonal contraceptives without measuring blood pressure - this is the single most important screening test 8
Don't assume all low-dose pills are equivalent for bleeding patterns - 20 μg formulations have higher breakthrough bleeding rates than 25-35 μg formulations 9
Don't overlook smoking status in women ≥35 years - this represents an absolute contraindication (Category 4) for ≥15 cigarettes/day 8
Don't forget that transdermal patches and vaginal rings have the same contraindications as oral COCs 7, 8 - they are not safer alternatives for women with cardiovascular risk factors
Extended Cycle Considerations
Once established on a standard regimen, extended-cycle use (eliminating or shortening the hormone-free interval) optimizes ovarian suppression and may improve contraceptive effectiveness, especially in adolescents who frequently miss pills 1. This approach also minimizes unscheduled bleeding over time 1.